MindWalk (NASDAQ: HYFT) maps 20+ partner clinical programs and HYFT AI platform

Rhea-AI Filing Summary

MindWalk Holdings Corp. released a report highlighting its role in creating over 20 partner-owned drug programs that originated from its antibody discovery work, with 10 currently in active Phase 1–3 clinical trials across multiple disease areas. The company explains that partners fully own and fund these clinical assets, while MindWalk’s contribution centers on discovery and candidate selection. It emphasizes its integrated model combining proprietary wet-lab antibody discovery, including camelid VHH nanobody discovery via the B cell Llama™ platform, with its HYFT® biological intelligence system and LensAI™ platform. MindWalk also notes a record of more than 400 peer-reviewed publications and patents and describes its HYFT® Knowledge Graph, which indexes hundreds of millions of biological patterns and billions of relationships to support AI-native drug discovery workflows.

Key Figures

Active clinical programs: 10 programs Total discovery-originated programs: Over 20 programs Scientific output: More than 400 publications and patents +2 more

5 metrics

Active clinical programs 10 programs Active Phase 1–3 trials derived from MindWalk discovery

Total discovery-originated programs Over 20 programs Partner-owned drug candidates with MindWalk discovery origins

Scientific output More than 400 publications and patents Peer-reviewed publications and patents from MindWalk lineage

HYFT patterns 660 million patterns Biological patterns indexed in HYFT Knowledge Graph

HYFT relationships 25 billion relationships Biological relationships captured in HYFT Knowledge Graph

Key Terms

HYFT, LensAI, B cell Llama, camelid nanobody, +2 more

6 terms

HYFT technical

"The HYFT® system and LensAI™ platform were developed independently as a purpose-built AI architecture"

LensAI technical

"The HYFT® system and LensAI™ platform were developed independently as a purpose-built AI architecture"

B cell Llama technical

"including camelid VHH nanobody discovery via the B cell Llama™ platform"

camelid nanobody technical

"including camelid VHH nanobody discovery via the B cell Llama™ platform"

A camelid nanobody is a very small, naturally occurring antibody fragment derived from animals such as llamas and camels; think of it as a compact, highly focused version of a conventional antibody that can bind a target like a molecular Velcro. Investors should care because these tiny biologics often enter tissues more easily, can be cheaper and faster to manufacture, and open different drug or diagnostic paths than traditional antibodies, affecting R&D value and partnering potential.

Knowledge Graph technical

"The Knowledge Graph that underpins HYFT® — 660 million biological patterns, 25 billion relationships"

A knowledge graph is a structured map that links facts about people, companies, products, and events so a computer can understand how they relate to one another. For investors, it turns scattered data—news, filings, research—into clear connections (like a labeled map) that reveal risks, hidden relationships, and opportunities faster, improving due diligence and decision-making without relying on a single document.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026.

Commission File Number: 001-39530

MindWalk Holdings Corp.

3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated May 18, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MINDWALK HOLDINGS CORP.
Date: May 18, 2026
	By:	/s/ Jennifer Bath
	Name:	Jennifer Bath
	Title:	President and Chief Executive Officer

99.1

The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company's work today.

AUSTIN, TX — May 2026 — MindWalk Holdings Corp. (NASDAQ: HYFT)

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is wholly owned, advanced, and funded by the partner. MindWalk’s contribution was the molecule itself — the immunization strategy, the discovery campaign, the lead identification, and the candidate selection that made clinical entry possible. In select cases that contribution extended into early development. The same wet-lab and AI capabilities that produced these programs are available to MindWalk’s partners today and are the foundation of the Company’s own proprietary portfolio. The full report, available Here, identifies each partner by program.

The significance of this record extends beyond the clinical count. The more than 400 peer-reviewed publications and patents produced through this work establish a scientific standard that is rare in this industry: a discovery capability that has consistently produced partner-owned clinical-stage assets across therapeutic areas and modalities. That standard is the measure against which MindWalk holds every subsequent capability, including B cell Llama™ camelid nanobody discovery and the HYFT® biological intelligence infrastructure. The HYFT® system and LensAI™ platform were developed independently as a purpose-built AI architecture — not derived from the wet-lab programs, but subsequently integrated with them, and now embedded in every internal MindWalk program. The Knowledge Graph that underpins HYFT® — 660 million biological patterns, 25 billion relationships, refined over 20 years of curation — is not a general-purpose AI substrate trained on public data. It is a function-aware representation of biological sequence space, built on biological pattern recognition derived from the breadth of the global biosphere, and now operating in direct integration with the wet-lab discovery workflows that produced these programs.

“Before AI was a hypothesis in life sciences, our scientists were generating the molecules that are now in clinical trials at our partners. That history is not a credential we display — it is a standard we hold ourselves to. When we bring a new capability into this organization, the question is always the same: can it meet the bar that wet-lab discovery set? HYFT® and LensAI™ were built by world-class scientists pursuing a singular focus: creating the most rigorous biological representation system ever developed. We integrated them because they cleared that bar. The result is a discovery organization where the biology and the AI interrogate each other — and where neither would be as good without the other.” — Dr. Jennifer Bath, PhD, Chief Executive Officer and President, MindWalk Holdings Corp.

KEY FACTS

•10 programs in active Phase 1–3 clinical trials; over 20 discovery-originated programs documented in total

•Clinical-stage programs include: ANX005 (Annexon Biosciences, Phase 3, Guilláin-Barré Syndrome, FDA Breakthrough Therapy designation); ARGX-119 (argenx, Phase 2/3, Congenital Myasthenic Syndrome); vudalimab / XmAb20717, XmAb306, XmAb808 (Xencor, Phase 1–2, solid tumors); CIT-013 (Citryll BV, Phase 2, rheumatoid arthritis and hidradenitis suppurativa); PMN310 (ProMIS Neurosciences, Phase 1b, Alzheimer’s disease); CLN-619 (Cullinan Oncology, Phase 1, solid tumors); OR502 (OncoResponse, Phase 1/2, solid tumors)

•Partners and collaborators include: Annexon Biosciences, argenx (NASDAQ: ARGX), Xencor (NASDAQ: XNCR), Citryll BV, ProMIS Neurosciences, Cullinan Oncology (NASDAQ: CGEM), OncoResponse, Sanofi Pasteur, Janssen Vaccines (Johnson & Johnson), Michael J. Fox Foundation, Perseus Science / ChemBio, IDEXX Laboratories (NASDAQ: IDXX)

•Discovery capability: Proprietary wet-lab antibody discovery across multiple modalities and species, including camelid VHH nanobody discovery via the B cell Llama™ platform — operating from MindWalk’s antibody discovery site in Victoria, British Columbia

•Biological intelligence infrastructure: HYFT® and LensAI™ were developed independently as a purpose-built AI architecture — built on biological pattern recognition derived from the breadth of the global biosphere — and subsequently integrated with MindWalk’s wet-lab discovery engine. The Knowledge Graph indexes 660 million biological patterns and 25 billion relationships, refined over 15 years of curation — enriching biological data at ingestion and compounding in analytical value with every program run on the platform.

•Publication record: Over 400 peer-reviewed publications and patents, originally published under ImmunoPrecise Antibodies (NASDAQ: IPA), Modiquest Research, and related entities, now operating as MindWalk Holdings Corp. (NASDAQ: HYFT) — reflecting a consistent scientific output across therapeutic areas, modalities, and discovery disciplines.

Independent analysis has identified data structure and orchestration as the gating factors for enterprise AI value and named drug discovery as the highest-consequence AI application environment — the category where reliability is paramount and the cost of a wrong answer is too high to absorb. MindWalk occupies that layer for life sciences. The HYFT®representation layer enriches biological data at ingestion and compounds in analytical value with every program run on the platform. That compounding is not a product claim. It is an architectural consequence of a substrate built on biological pattern recognition derived from the breadth of the global biosphere — and now operating in direct integration with the wet-lab discovery workflows that produced these programs. The Company will provide further updates on its biological intelligence infrastructure, commercial programs, and platform development in the coming months.

Access the report: Discovery-to-Clinic

ABOUT MINDWALK HOLDINGS CORP.

MindWalk Holdings Corp. (NASDAQ: HYFT) is a bio-native AI company building the biological intelligence infrastructure that life sciences AI and agentic AI require. Its proprietary HYFT® system functions as the AI-ready data substrate for life sciences — a function-aware representation organized around HYFT pattern-objects that span sequence and structural biology, refined over 20 years of curation

by a continuously evolving Knowledge Graph of 660 million biological patterns and 25 billion relationships, that enriches data at ingestion and compounds in analytical value with every program run on the platform. The LensAI™ platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic AI workflows pharma is racing to deploy. MindWalk’s architecture is designed so that the HYFT®representation layer — not any individual AI model — is the durable, compounding competitive asset. The HYFT® system and LensAI™platform are fully integrated with MindWalk’s antibody discovery engine, operating in direct integration with the wet-lab workflows that have consistently produced clinical-stage assets for partners across therapeutic areas and modalities. The Company operates its antibody discovery laboratory in Victoria, British Columbia; its biological AI and technology operations through BioStrand in Belgium; and United States offices in Fargo, North Dakota, Minneapolis, Minnesota, and Boston, Massachusetts.

Trademarks: HYFT, LensAI, HYFT Base, HYFT Matrix, HYFT Prime, B cell Llama, B Cell Select are trademarks of MindWalk Holdings Corp. or its subsidiaries. All other trademarks are the property of their respective owners.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by terms such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” or similar expressions, or by statements that certain actions, events, or results are expected to occur or be achieved.

Forward-looking statements in this press release include, without limitation, statements regarding: the continuation and advancement of partner-owned clinical programs derived from MindWalk antibody discovery work; the characterization of MindWalk’s antibody discovery platform lineage and its translational record; the expected concurrent advancement of MindWalk’s B cell Llama™ camelid nanobody platform and the HYFT® / LensAI™ AI-native platform; the Company’s ability to apply native-repertoire wet-lab discovery and AI-native discovery to produce partner clinical-stage assets in the future; and statements regarding the competitive, structural, or functional characteristics and compounding value of the HYFT® biological pattern system and LensAI™platform. Past success of one platform generation does not ensure clinical or commercial success of any other generation, including AI-native discovery.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to clinical trial outcomes at partner companies; partner program continuation or discontinuation; regulatory determinations; competition; intellectual property risks; the technical performance of AI-based discovery methods; and capital markets conditions. Additional information is available in MindWalk’s Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. Nothing in this press release constitutes investment advice. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor Relations Contact

Louie Toma, CPA, CFA

Managing Director, CoreIR

investors@mindwalkai.com

Source: MindWalk Holdings Corp.

FAQ

What did MindWalk Holdings Corp. (NASDAQ: HYFT) disclose in this 6-K filing?

MindWalk Holdings Corp. reported a new analysis of its discovery-originated drug programs and AI platform. The company highlighted more than 20 partner-owned clinical candidates and detailed its integrated wet-lab and HYFT® / LensAI™ biological intelligence infrastructure supporting drug discovery.

How many MindWalk-derived drug programs are in clinical trials?

MindWalk states that 10 partner-owned programs originating from its antibody discovery work are in active Phase 1–3 clinical trials. These span oncology, immunology, neurology, and infectious disease, and are advanced and funded by partners while MindWalk contributed the underlying antibody discovery and candidate selection.

Which notable partners are associated with MindWalk’s discovery-originated programs?

Partners include Annexon Biosciences, argenx, Xencor, Citryll BV, ProMIS Neurosciences, Cullinan Oncology, OncoResponse, Sanofi Pasteur, Janssen Vaccines, the Michael J. Fox Foundation, Perseus Science / ChemBio, and IDEXX Laboratories, reflecting broad collaboration across biopharma and research organizations.

What is the HYFT® biological intelligence system described by MindWalk?

HYFT® is described as an AI-ready biological data substrate built on pattern recognition across sequence and structural biology. Its Knowledge Graph indexes 660 million biological patterns and 25 billion relationships, enriching data at ingestion and supporting LensAI™-driven discovery and portfolio decisions.

How does MindWalk combine AI with wet-lab antibody discovery?

MindWalk explains that HYFT® and LensAI™ are fully integrated with its antibody discovery engine. Wet-lab capabilities, including B cell Llama™ camelid nanobody discovery, operate in direct integration with HYFT®-powered workflows to support target discovery, candidate diligence, and partner clinical-stage assets.

What scientific track record does MindWalk report from its legacy platforms?

The company cites more than 400 peer-reviewed publications and patents originating under ImmunoPrecise Antibodies, Modiquest Research, and related entities. This output, now operating under MindWalk Holdings Corp., spans diverse therapeutic areas, modalities, and discovery disciplines over many years.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 31.9 KB